Adaptive Biotechnologies announced it will separate its profitable Minimal Residual Disease (MRD) diagnostics business, which has grown significantly and reached profitability, from its Immune Medicine business, which focuses on AI-driven immune data discovery. The company believes separating these businesses will unlock their full potential, with MRD continuing under Adaptive and Immune Medicine exploring strategic alternatives outside the company. This move aims to enhance growth, value creation, and impact on patients, with a preferred separation path expected by the end of 2026.
Adaptive Biotechnologies announced a proposed private offering of $250 million in convertible senior notes due 2031, with an option for an additional $37.5 million. The proceeds will primarily repay the OrbiMed Purchase Agreement, repurchase up to $2...
Harvest Investment Services has sold 356,000 shares of Adaptive Biotechnologies, totaling approximately $5.7 million. This significant sale may impact the stock's market perception and price. Investors should watch for any further moves by major shar...
